In an interview with Page Six, he noted, "I feel like a normal person
Table of Contents Understanding the Oral GLP1 Opportunity Reframing the Market: From Weight Loss to WholePerson Outcomes Messaging that Matters: Clarity, Context, and Credibility Channel Choices in a Multiformat Environment Addressing Access, Affordability, and Health Inequities Staying Honest About Safety and Expectations Measuring Success in a Complex Therapeutic Landscape FAQs Understanding the Oral GLP1 Opportunity The arrival of oral GLP1 therapies is transforming treatment pathways
Levels of pro-inflammatory cytokines, reactive oxygen species (ROS), and malondialdehyde (MDA) (oxidative stress markers) were detected
The availability of highly potent products has significantly shifted the risk profile
Starting low and increasing gradually, ideally with guidance from a clinician or dietitian, can improve tolerability
Important Epithalon Research Limitations The literature is concentrated within a small research network and relies heavily on preclinical models